Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Scores highest PAT of Rs. 118 crore in FY25
The company has posted net profit of Rs. 338.55 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 55.36 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
Subscribe To Our Newsletter & Stay Updated
